Ongoing clinical trials are evaluating the combination of HuMax-IL8 (BMS-986253) and PD-1/PD-L1-blocking immunotherapies in melanoma and advanced cancers (NCT03400332; NCT04572451), hepatocellular carcinoma (NCT04050462), prostate cancer (NCT03689699), pancreatic cancer (NCT02451982), head and neck squamous-cell carcinoma (NCT04848116), and colon carcinoma (NCT03026140) (Table 2). Here, CXCL8 is linked to hepatocellular carcinoma.